WO2003048116A3 - Esters and amides as ppar-alpha agonists ____________ - Google Patents

Esters and amides as ppar-alpha agonists ____________ Download PDF

Info

Publication number
WO2003048116A3
WO2003048116A3 PCT/IB2002/005064 IB0205064W WO03048116A3 WO 2003048116 A3 WO2003048116 A3 WO 2003048116A3 IB 0205064 W IB0205064 W IB 0205064W WO 03048116 A3 WO03048116 A3 WO 03048116A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
compounds
preparation
novel
alpha agonists
Prior art date
Application number
PCT/IB2002/005064
Other languages
French (fr)
Other versions
WO2003048116A2 (en
Inventor
Debnath Bhuniya
Saibal Kumar Das
Gurram Ranga Madhavan
Javed Iqbal
Ranjan Chakrabarti
Reeba Kannimel Vikramadithyan
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA20040705344A priority Critical patent/UA82835C2/en
Priority to MXPA04005257A priority patent/MXPA04005257A/en
Priority to AU2002351069A priority patent/AU2002351069A1/en
Priority to EA200400762A priority patent/EA008947B1/en
Priority to EP02785781A priority patent/EP1453795A2/en
Priority to HU0402550A priority patent/HUP0402550A3/en
Priority to KR10-2004-7008538A priority patent/KR20040066866A/en
Priority to JP2003549308A priority patent/JP2005511686A/en
Priority to BR0214675-4A priority patent/BR0214675A/en
Priority to CA002469227A priority patent/CA2469227A1/en
Priority to IL16218502A priority patent/IL162185A0/en
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Priority to NZ533311A priority patent/NZ533311A/en
Priority to YUP-481/04A priority patent/RS48104A/en
Publication of WO2003048116A2 publication Critical patent/WO2003048116A2/en
Priority to HR20040485A priority patent/HRP20040485A2/en
Publication of WO2003048116A3 publication Critical patent/WO2003048116A3/en
Priority to NO20042805A priority patent/NO20042805L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/06—Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C07C211/46—Aniline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/53—X and Y not being nitrogen atoms, e.g. N-sulfonylcarbamic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)

Abstract

The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to compounds of the general formula (I) which are predominantly PPAR alpha agonists, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them The present invention also relates to processes for the preparation of novel compounds of formula (I), novel intermediates, processes for their preparation, use of the novel intermediates in the preparation of the above said compounds and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds.
PCT/IB2002/005064 2001-12-03 2002-12-02 Esters and amides as ppar-alpha agonists ____________ WO2003048116A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
UA20040705344A UA82835C2 (en) 2001-12-03 2002-02-12 ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
IL16218502A IL162185A0 (en) 2001-12-03 2002-12-02 Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
CA002469227A CA2469227A1 (en) 2001-12-03 2002-12-02 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP02785781A EP1453795A2 (en) 2001-12-03 2002-12-02 Esters and amides as ppar-alpha agonists
AU2002351069A AU2002351069A1 (en) 2001-12-03 2002-12-02 Esters and amides as PPAR-alpha agonists
KR10-2004-7008538A KR20040066866A (en) 2001-12-03 2002-12-02 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2003549308A JP2005511686A (en) 2001-12-03 2002-12-02 Novel compounds and their use in medicine, processes for their preparation and pharmaceutical compositions containing them
MXPA04005257A MXPA04005257A (en) 2001-12-03 2002-12-02 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them.
EA200400762A EA008947B1 (en) 2001-12-03 2002-12-02 PRARα AGONISTS AND USE THEREOF
HU0402550A HUP0402550A3 (en) 2001-12-03 2002-12-02 Esters and amides as ppar-alpha agonists
BR0214675-4A BR0214675A (en) 2001-12-03 2002-12-02 Novel compounds and their use in medicine, processes for their preparation and pharmaceutical compositions containing them
NZ533311A NZ533311A (en) 2001-12-03 2002-12-02 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
YUP-481/04A RS48104A (en) 2001-12-03 2002-12-02 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing theim
HR20040485A HRP20040485A2 (en) 2001-12-03 2004-05-31 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NO20042805A NO20042805L (en) 2001-12-03 2004-07-02 New compounds and their use in medicine, methods of their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN971MA2001 2001-12-03
IN971/MAS/2001 2001-12-03

Publications (2)

Publication Number Publication Date
WO2003048116A2 WO2003048116A2 (en) 2003-06-12
WO2003048116A3 true WO2003048116A3 (en) 2004-06-10

Family

ID=29596806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005064 WO2003048116A2 (en) 2001-12-03 2002-12-02 Esters and amides as ppar-alpha agonists ____________

Country Status (21)

Country Link
US (2) US7314889B2 (en)
EP (1) EP1453795A2 (en)
JP (1) JP2005511686A (en)
KR (1) KR20040066866A (en)
CN (1) CN1697828A (en)
AU (1) AU2002351069A1 (en)
BR (1) BR0214675A (en)
CA (1) CA2469227A1 (en)
CO (1) CO5580760A2 (en)
EA (1) EA008947B1 (en)
HR (1) HRP20040485A2 (en)
HU (1) HUP0402550A3 (en)
IL (1) IL162185A0 (en)
MX (1) MXPA04005257A (en)
NO (1) NO20042805L (en)
NZ (1) NZ533311A (en)
PL (1) PL370554A1 (en)
RS (1) RS48104A (en)
UA (1) UA82835C2 (en)
WO (1) WO2003048116A2 (en)
ZA (1) ZA200404261B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100989394B1 (en) * 2002-10-21 2010-10-25 얀센 파마슈티카 엔.브이. Substituted tetralins and indanes and their use
CA2502661A1 (en) * 2002-10-21 2004-05-06 Janssen Pharmaceutica, N.V. Substituted tetralins and indanes
CA2503405A1 (en) * 2002-10-21 2004-05-06 Janssen Pharmaceutica, N.V. Treating syndrome x with substituted tetralins and indanes
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20070093476A1 (en) * 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
EP1687299A1 (en) * 2003-11-20 2006-08-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treamtment and/or prevention of disorders modulated by a ppar
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
WO2005110468A2 (en) * 2004-05-10 2005-11-24 The Burnham Institute Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia
CA2570820A1 (en) * 2004-06-10 2006-01-05 Dr. Reddy's Laboratories Limited Basic salts and monohydrates of certain alpha, beta-proprionic acid derivative
FR2875805B1 (en) * 2004-09-27 2006-12-29 Genfit S A SUBSTITUTED N- (BENZYL) PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION AND USES
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050390A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
KR100852962B1 (en) * 2007-11-12 2008-08-20 주식회사 뉴로테크 Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
BRPI1008752B1 (en) 2009-02-16 2020-02-11 Nogra Pharma Limited ALKYLAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
US11806352B2 (en) 2010-05-19 2023-11-07 Upfield Europe B.V. Theobromine for increasing HDL-cholesterol
US8815265B2 (en) * 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
EP2588593B1 (en) 2010-06-30 2017-08-23 Avon Products, Inc. Compositions and methods for stimulating magp-1 to improve the appearance of skin
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8455518B2 (en) * 2010-12-28 2013-06-04 Avon Products, Inc. Method of treating skin with microRNA modulators
JP6301844B2 (en) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド How to treat fibrosis
KR20150002819A (en) 2012-04-18 2015-01-07 노그라 파마 리미티드 Methods of treating lactose intolerance
US20150197536A1 (en) * 2012-07-28 2015-07-16 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
CN113825739A (en) * 2019-02-08 2021-12-21 诺格拉制药有限公司 Process for preparing 3- (4' -aminophenyl) -2-methoxypropionic acid and analogs and intermediates thereof
CN110590615A (en) * 2019-10-03 2019-12-20 南京施倍泰生物科技有限公司 Novel ferulic acid sulfonate derivatives, and preparation method and application thereof
CN110627690A (en) * 2019-10-03 2019-12-31 南京施倍泰生物科技有限公司 Novel p-coumaric acid sulfonate derivative and preparation method and application thereof
CN113968781A (en) * 2021-11-11 2022-01-25 上海吉奉生物科技有限公司 Synthesis method of (S) -2-hydroxy-3-o-methylpropanoic acid
CN114685323B (en) * 2022-04-24 2023-01-06 南京大学 Cinnamic amide structure-based sulfophenol ester derivatives and preparation method and application thereof
CN114773238B (en) * 2022-04-24 2023-03-24 南京大学 Phenylpropylidene acylated p-chlorobenzenesulfonyl ferulic acid ester derivative and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062870A1 (en) * 1998-06-04 1999-12-09 Astrazeneca Ab New 3-aryl-2-hydroxypropionic acid derivative iii
WO1999062872A1 (en) * 1998-06-04 1999-12-09 Astrazeneca Ab New 3-aryl-2-hydroxypropionic acid derivative (i)
WO1999062871A1 (en) * 1998-06-04 1999-12-09 Astrazeneca Ab New 3-aryl propionic acid derivatives and analogs
WO2001025181A1 (en) * 1999-10-01 2001-04-12 Eisai Co., Ltd. Carboxylic acid derivatives and drugs containing the same
WO2001040172A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab New tri-substituted phenyl derivatives and analogues

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062870A1 (en) * 1998-06-04 1999-12-09 Astrazeneca Ab New 3-aryl-2-hydroxypropionic acid derivative iii
WO1999062872A1 (en) * 1998-06-04 1999-12-09 Astrazeneca Ab New 3-aryl-2-hydroxypropionic acid derivative (i)
WO1999062871A1 (en) * 1998-06-04 1999-12-09 Astrazeneca Ab New 3-aryl propionic acid derivatives and analogs
WO2001025181A1 (en) * 1999-10-01 2001-04-12 Eisai Co., Ltd. Carboxylic acid derivatives and drugs containing the same
EP1216980A1 (en) * 1999-10-01 2002-06-26 Eisai Co., Ltd. Carboxylic acid derivatives and drugs containing the same
WO2001040172A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab New tri-substituted phenyl derivatives and analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P.M. DHAMASENA, ET AL.: "The effect of electro-withdrawing groups in the amide and bromo components on the yield of the Goldberg reaction", JOURNAL OF CHEMICAL RESEARCH (MINIPRINT), no. 8, 1994, Royal Society of Chemistry, Letchworth, GB, pages 1601 - 1611, XP008015283 *

Also Published As

Publication number Publication date
US20030229083A1 (en) 2003-12-11
ZA200404261B (en) 2005-09-08
MXPA04005257A (en) 2004-10-11
BR0214675A (en) 2004-10-19
HUP0402550A3 (en) 2009-04-28
RS48104A (en) 2007-02-05
KR20040066866A (en) 2004-07-27
HUP0402550A2 (en) 2005-07-28
UA82835C2 (en) 2008-05-26
IL162185A0 (en) 2005-11-20
US7598293B2 (en) 2009-10-06
JP2005511686A (en) 2005-04-28
CO5580760A2 (en) 2005-11-30
NO20042805L (en) 2004-07-02
US7314889B2 (en) 2008-01-01
EP1453795A2 (en) 2004-09-08
CA2469227A1 (en) 2003-06-12
NZ533311A (en) 2007-05-31
US20070142470A1 (en) 2007-06-21
EA008947B1 (en) 2007-10-26
WO2003048116A2 (en) 2003-06-12
HRP20040485A2 (en) 2005-08-31
EA200400762A1 (en) 2004-12-30
AU2002351069A1 (en) 2003-06-17
CN1697828A (en) 2005-11-16
PL370554A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
WO2003048116A3 (en) Esters and amides as ppar-alpha agonists ____________
WO1999008501A3 (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
DE69831868D1 (en) Antithrombosemittel
YU60701A (en) Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical composition containing them
IL142649A0 (en) Azole derivatives
WO2002010154A3 (en) Substituted heterocyclic amides
MXPA02012033A (en) 2-aminocarbonyl-9h-purine derivatives.
NZ504106A (en) Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
AU2055500A (en) Aromatic amides
IL133623A0 (en) Antithrombotic agents
WO2003084937A3 (en) Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
AU2054700A (en) Antithrombotic amides
AU6966498A (en) Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties
WO2001090097A3 (en) Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them
CA2397828A1 (en) Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
YU75101A (en) Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
TW200704633A (en) Process for the preparation of sulfonamide derivatives
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
DE60114640D1 (en) Antithrombosemittel
WO2007004041A3 (en) New compounds and their pharmaceutical use
WO2003093247A3 (en) Antibacterial agents
UA72883C2 (en) Bicyclic compounds, a method for preparing thereof and pharmaceutical compositions containing them
AU7109798A (en) Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties
WO2002062798A3 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
MY136600A (en) Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-481/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002785781

Country of ref document: EP

Ref document number: 162185

Country of ref document: IL

Ref document number: 2002351069

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/04261

Country of ref document: ZA

Ref document number: P20040485A

Country of ref document: HR

Ref document number: 04050434

Country of ref document: CO

Ref document number: 200404261

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2004/005257

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 533311

Country of ref document: NZ

Ref document number: 2469227

Country of ref document: CA

Ref document number: 2003549308

Country of ref document: JP

Ref document number: 1020047008538

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028266234

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200400762

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20040260

Country of ref document: UZ

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2002785781

Country of ref document: EP